Dr. Bruce D. Forrest Joins Skymount Medical as Chief Medical Officer, Strengthening Team for Future Growth

Article content material

Bruce D. Forrest, MD, MBA brings over 30 years of worldwide management in pharmaceutical growth

CALGARY, Alberta and NEW ORLEANS, June 22, 2022 (GLOBE NEWSWIRE) — Skymount Medical, a drug discovery firm utilizing a extremely predictive synthetic intelligence (AI) platform to repurpose and construct new medication and modern therapies, introduced at this time that main pharmaceutical trade govt, Bruce D. Forrest, MD, MBA, has joined the Firm as Chief Medical Officer.

Article content material

Previously a divisional Senior Vice President at Pfizer, Inc. and earlier than that Wyeth Prescription drugs, Inc., Bruce D. Forrest, MD, MBA brings over 30 years of worldwide management in pharmaceutical growth, with in depth experience in vaccines and biopharmaceuticals growth in each main and rising markets. He led medical actions supporting the market authorization for RotaShield® (EU), Prevnar® (World), and FluMist®, and developed profitable methods for the combination and coordination of growth actions internationally. View Dr. Forrest’s full bio right here.

“Dr. Forrest has established a fame for creating modern options to advanced product growth challenges. His in depth medical background and confirmed management will strengthen our efforts and help the progress of our AI platform. We sit up for Dr. Forrest’s insights as we work to seize the total affect of this very thrilling intersection of know-how and drugs,” stated Zubin Kothawala, Chief Govt Officer of Skymount Medical.

Article content material

Dr. Forrest was the founding father of B D Forrest & Firm, a prescription drugs trade consultancy agency, which was acquired by Hudson Improvements in 2018.

“Skymount Medical’s AI platform has proven success in accelerating each section of drug discovery. I’m thrilled to be a part of the crew dedicated to advancing a know-how with the potential to revolutionize the best way therapeutics are developed, all with the aim of enhancing well being outcomes and offering entry to efficient therapies for sufferers,” stated Dr. Forrest.

About DeepDrug™

The DeepDrug™ synthetic intelligence platform was developed by an interdisciplinary crew of Louisiana State College (LSU) researchers. The DeepDrug™ platform makes use of a number of key elements to ship a state-of-the-art compound and system technology functionality that significantly reduces the time and value related to conventional drug discovery.

Article content material

About Skymount Medical Inc.

Skymount Medical is a man-made intelligence and biotechnology firm with the unique rights to DeepDrug™️, a patent-pending AI platform, which Skymount Medical makes use of to speed up drug discovery and growth. Alongside Louisiana State College, the corporate is presently creating mixture therapies to battle COVID-19 and all coronavirus strains. Moreover, Skymount Medical is planning to develop therapeutics for different infectious ailments, new antibiotics for antibiotic-resistant micro organism and different uncommon indications. Go to skymountmed.com to study extra.

Buyers Relations Contact

Lisa M. Wilson, In-Website Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com